We also discuss potential pitfalls of this approach (resistant dormant state, activation of pro-metastatic pathways) that manifest the integrated nature of the cancer cell response and that must be taken into account in pre-clinical evaluation of CRL inhibitors. This evidence concerns the gene IL31RA and cancer.